97141 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
VHH ANTIBODIES AND USES THEREOF
#2PHARMACEUTICAL COMPOSITION FOR AMELIORATING ACUTE LUNG INJURY AND ACUTE WORSENING OF PULMONARY FIBROSIS
#3Vaccines and Antibodies for the Treatment and Prevention of Neurodegenerative Disorders and Inflammation Related Health Conditions
#4COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN
#5Nanobody platform, Peptide-modified Nanobody, Production Process, and Use
#6DECREASING STAPHYLOCOCCUS AUREUS INFECTIONS IN COLONIZED PATIENTS
#7METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS
#8COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SpA) VARIANTS
#9TREATMENT OF STAPHYLOCOCCUS RELATED DISEASES
#10ANTIBODY FOR HAIR IMPROVEMENT USE
#11ANTIBODY DIRECTED AGAINST S. AUREUS CLUMPING FACTOR A (ClfA)
#12NORA INHIBITORS AND METHODS OF USE
#13Methods and Compositions of Thermostabilized Single Domain Antibodies
#14ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF
#15COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN
#16Identification of Polynucleotides Associated with a Sample
#17PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING STAPHYLOCOCCUS AUREUS
#18Composition for the treatment of antibody deficiencies
#19COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SpA) VARIANTS
#20ANTIBODY SPECIFIC TO STAPHYLOCOCCUS AUREUS, THERAPEUTIC METHOD AND DETECTION METHOD USING SAME
#21PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING STAPHYLOCOCCUS AUREUS
#22SINGLE DOMAIN ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS
#23Peptides and antibodies for the removal of biofilms
#24ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF
#25COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY
#26Identification of Polynucleotides Associated with a Sample
#27TREATMENT OF HIDRADENITIS SUPPURATIVA
#28Method of Cleaning and/or Sanitizing a Separation Matrix
#29Compositions and methods for treating and preventing staphylococcus aureus infections
#30METHODS, ANTIBODIES OR ANTIGEN BINDING FRAGMENTS AND OTHER TOOLS FOR DETERMINING TARGET MOLECULES
#31COMPOSITION FOR DIAGNOSING SUSCEPTIBILITY OF STAPHYLOCOCCUS AUREUS TO ANTIBIOTICS, AND USE THEREOF
#32IMMUNOGENIC PEPTIDE AGAINST GROUP A STREPTOCOCCUS
#33POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF
#34METHODS AND COMPOSITIONS FOR EVALUATING AND TREATING FIBROSIS
#35INERT FORMAT
#36STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF
#37Identification of Polynucleotides Associated with a Sample
#38DEVICE, PROCEDURE AND SYSTEM FOR DETECTING BACTERIAL PATHOGENS INCLUDING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS OR CLOSTRIDIUM DIFFICILE
#39Chimeric canine anti-CD20 antibody
#40Separation Method
#41TREATMENT OF HIDRADENITIS SUPPURATIVA
#42FC-REGION VARIANTS WITH IMPROVED PROTEIN A-BINDING
#43Cellular factors involved in the cytotoxicity of leukocidins: novel therapeutic targets
#44COMPOSITIONS AND METHODS FOR TREATMENT OF LIQUID CANCERS
#45Compositions and methods for the treatment of immunodeficiency
#46ANTIBODIES AND METHODS OF USE THEREOF IN TREATMENT OF INFECTIOUS DISEASE
#47ANTI-ALPHA-HEMOLYSIN ANTIBODY AND USE THEREOF
#48METHOD FOR SEPARATION OF ANTIBODIES OR ANTIBODY FRAGMENTS BEING DEVOID OF AN FC REGION CAPABLE OF BINDING TO PROTEIN A
#49Human Immunoglobulin Against Methicillin-Resistant Staphylococcus Aureus, Preparation Method Therefor, And Use Thereof
#50Binding moieties for biofilm remediation
#51Compositions and methods for treating and preventing infections
#52Compositions and methods for treating a COVID-19 infection
#53COMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASE
#54ATTENUATION OF BACTERIAL INFECTION
#55PATHOGEN BINDING METHODS AND COMPOSITIONS
#56METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES
#57COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN
#58TREATMENT OF HIDRADENITIS SUPPURATIVA
#59Decreasing infections in colonized patients
#60COMBINATIONS OF ANTI-STAPHYLOCOCCUS AUREUS ANTIBODIES
#61Antibody directed against clumping factor A (ClfA)
#62Treatment of staphylococcal disorders
#63Method for isolation of soluble polypeptides
#64IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
#65Composition for the treatment of antibody deficiencies
#66Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
#67Antibodies directed against leukotoxins
#68POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF
#69METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS
#70ANTIBODY FOR HAIR IMPROVEMENT USE
#71Compositions and methods related to protein A (SpA) variants
#72FC-REGION VARIANTS WITH MODIFIED FCRN- AND PROTEIN A-BINDING PROPERTIES
#73DIMERIC PROTEIN WITH TRIPLE MUTATIONS
#74Peptides and antibodies for the removal of biofilms
#75TREATMENT OF STAPHYLOCOCCUS RELATED DISEASES
#76TREATMENT OF HIDRADENITIS SUPPURATIVA
#77CHIMERIC CANINE ANTI-CD20 ANTIBODY
#78Human antibodies to Hemolysin A toxin
#79Methods and compositions related to immunizing against lung diseases and conditions
#80BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND A STAPHYLOCOCCUS TARGET ANTIGEN AND A COMPLEMENT COMPONENT AND USES THEREOF
#81Compositions and methods for the treatment of immunodeficiency
#82Compositions and methods for modified b cells expressing reassigned biological agents
#83STAPHYLOCOCCAL COAGULASE ANTIGENS AND METHODS OF THEIR USE
#84Mutated immunoglobulin-binding polypeptides
#85Antibody specific to , therapeutic method and detection method using same
#86Immunogenic peptide against group a
#87Antibacterial antibody and use thereof
#88Compositions and Methods for Treating and Preventing Staphylococcus Aureus Infections
#89Cellular factors involved in the cytotoxicity of leukocidins: novel therapeutic targets
#90Antibodies to surface determinants
#91Methods of treating and preventing infections and associated conditions
#92BINDING MOLECULES TARGETING PATHOGENS
#93Inert format
#94Anti-glucosaminidase passive immunization for infections
#95Immunogenic compositions comprising leukocidin LukA and LukB derived polypeptides
#96Compositions and methods for antibodies targeting staphylococcal leukotoxins
#97Proteins and nucleic acids useful in vaccines targeting
#98Method of cleaning and/or sanitizing a separation matrix
#99Immunoglobulins and variants directed against pathogenic microbes
#100Compositions and use of a fibrinogen binding motif present in EFB and COA for therapeutics and vaccines against
#101Separation method
#102Method of storing a separation matrix
#103Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
#104Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
#105Live attenuated vaccines
#106Binding moieties for biofilm remediation
#107IMMUNOGENIC COMPOSITION FOR USE IN VACCINATION AGAINST STAPHYLOCOCCI
#108Anti-antibodies and uses thereof
#109Compositions and methods related to protein A (SpA) variants
#110Chimeric canine anti-CD20 antibody
#111Compositions and methods for treating and preventing infections
#112ANTIBODIES AND METHODS OF USE THEREOF IN TREATMENT OF INFECTIOUS DISEASE
#113Polypeptide epitopes of and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
#114Methods of treating -associated diseases
#115Antibodies directed against leukotoxins
#116Combinations of anti-antibodies
#117Antibody directed against clumping factor a (ClfA)
#118Proteins and nucleic acids useful in vaccines targeting
#119Human antibodies to hemolysin A toxin
#120Human monoclonal antibodies to lukab toxin
#121TREATMENT OF HIDRADENITIS SUPPURATIVA
#122Compositions containing anti-HIV ostrich antibodies
#123Compositions and methods for modified B cells expressing reassigned biological agents
#124leukocidins, therapeutic compositions, and uses thereof
#125Anti-glucosaminidase passive immunization for infections
#126FUSION POLYPEPTIDES DERIVED FROM STAPHYLOCOCCUS AUREUS ANTIGENS
#127Passive immunization for infections
#128Process for the preparation of an antibody-rifamycin conjugate
#129CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS
#130DEVICE, PROCEDURE AND SYSTEM FOR DETECTING BACTERIAL PATHOGENS INCLUDING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS OR CLOSTRIDIUM DIFFICILE
#131Nucleic acids for single-domain antibodies with thermal stability under cytoplasmic expression
#132Single-domain antibody fusion proteins with the acid tail of alpha-synuclein
#133Chimeric canine anti-CD20 antibody
#134Variant antibodies that bind AIP2
#135Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
#136Crystal structure of clumping factor A in complex with fibrinogen derived peptide and uses thereof
#137Immunoglobulins directed to bacterial, viral and endogenous polypetides
#138Mutated immunoglobulin-binding polypeptides
#139Methods of treating and preventing infections and associated conditions
#140Fc-region variants with improved protein A-binding
#141Compositions and methods for treating and preventing infections
#142Poly-n-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
#143Compositions and methods for anti-staphylococcal biologic agents
#144Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
#145Compositions and methods related to antibodies that neutralize coagulase activity during disease
#146Bispecific antigen-binding molecules that bind a target antigen and a complement component and uses thereof
#147Method for isolation of soluble polypeptides
#148METHODS OF USING ANTI-ALPHA TOXIN ANTIBODY
#149Immunogenic composition for use in vaccination against staphylococci
#150Binding moieties for biofilm remediation
#151FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES
#152Antibody and antibody-containing composition
#153Antibodies to surface determinants
#154Methods of treating -associated diseases
#155Peptides and antibodies for the removal of biofilms
#156materials and methods
#157Antibody specific to , therapeutic method and detection method using same
#158Targeting of ligand binding sites in ClfA
#159Subtractive immunoassay method and lateral flow immunochromatography assay strip for performing the method
#160Immunoglobulin-binding proteins and their use in affinity purification
#161Proteins and nucleic acids useful in vaccines targeting
#162GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
#163Compositions and methods for the treatment of immunodeficiency
#164Staphylococcal coagulase antigens and methods of their use
#165Treatment of hidradenitis suppurativa
#166USE OF ALPHA-TOXIN FOR TREATING AND PREVENTING STAPHYLOCOCCUS INFECTIONS
#167Compositions and methods for modified B cells expressing reassigned biological agents
#168Human antibodies to Hemolysin A toxin
#169ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY COMBINATION PREPARATION
#170COMPOSITIONS AND METHODS FOR DETECTING STAPHYLOCOCCOUS INFECTIONS
#171ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF
#172Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
#173Method for improving antibody
#174BINDING MOLECULES TARGETING PATHOGENS
#175ANTIBODY DIRECTED AGAINST IMMUNOGLOBULIN-BINDING PROTEINS OF S. AUREUS
#176leukocidins, therapeutic compositions, and uses thereof
#177High affinity antibodies that neutralize enterotoxin B
#178Separation method
#179Compositions and methods for the treatment of immunodeficiency
#180ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
#181Antibody and antibody-containing composition
#182Methods of treating and preventing infections and associated conditions
#183Anti-glucosaminidase passive immunization for infections
#184Anti-glucosaminidase passive immunization for infections
#185Anti-infective binding proteins that bind AIP2
#186Anti-wall teichoic antibodies and conjugates
#187Compositions and methods related to Protein A (SpA) Variants
#188Compositions and methods for treating and preventing infections
#189Fc-region variants with modified FcRn- and protein A-binding properties
#190Separation matrix
#191COMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASE
#192Method for purification of monoclonal antibodies
#193Protein A Binding Polypeptides, Anti-EphA2 Antibodies and Methods of Use Thereof
#194Process for the preparation of an antibody-rifamycin conjugate
#195materials and methods
#196Vaccines against serotype 8
#197Compositions and methods for phagocyte delivery of anti-staphylococcal agents
#198Immunoglobulins and variants directed against pathogenic microbes
#199Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
#200Compositions and methods related to antibodies to Staphylococcal protein A
#201Treatment of microbial infections
#202Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
#203Immunoglobulins and variants directed against pathogenic microbes
#204Treatment of polybacterial infections
#205Capsular gram-positive bacteria bioconjugate vaccines
#206High affinity antibodies that neutralize enterotoxin B
#207Gram-positive bacteria specific binding compounds
#208Method of treating protozoal gastrointestinal disorders in immunocompromised patients
#209FC-REGION VARIANTS WITH IMPROVED PROTEIN A-BINDING
#210FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES
#211Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
#212Anti-glucosaminidase passive immunization for infections
#213Compositions and methods for treating and preventing infections
#214Methods of treating and preventing infections and associated conditions
#215Antibodies against and uses therof
#216Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
#217Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
#218Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
#219Antibody and antibody-containing composition
#220ANTIBODIES DIRECTED AGAINST THE LukGH (LukAB) TOXIN OF STAPHYLOCOCCUS AUREUS AND ANTIBODY SEQUENCES
#221Peptide core-based multi-arm linkers for treating infectious diseases
#222Method of purifying monoclonal antibodies
#223Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
#224Opsonic and protective monoclonal antibodies against gram-positive pathogens
#225SpA5 mutant, composition comprising mutant and preparation method and use thereof
#226Compositions and methods for treating and preventing infections
#227Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices
#228Methods of treating -associated diseases
#229CROSS-REACTIVE STAPHYLOCOCCUS AUREUS ANTIBODY SEQUENCES
#230Binding moieties for biofilm remediation
#231Antibody purification method, antibody obtained therefrom, novel antibody purification method using cation exchanger, and antibody obtained therefrom
#232Live attenuated vaccines
#233Compositions and the Use of Fibrinogen Binding Motif Presence in EFB and COA for Vaccine Against Staphylococcus Aureus and Drug Delivery
#234Gram-positive bacteria specific binding compounds
#235Multimeric immunoglobulin-binding domain
#236Crystal Structure of Staphylococcus Aureus Clumping Factor A in Complex with Fibrinogen Derived Peptide and Uses Thereof
#237IMMUNOTHERAPEUTIC TARGETS AGAINST STAPHYLOCOCCUS AUREUS
#238Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
#239Cellular factors involved in the cytotoxicity of leukocidins: novel therapeutic targets
#240GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
#241Protein ligand for affinity isolation matrix
#242Chromatography matrices including novel protein a based ligands
#243Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
#244Compositions and methods related to antibodies to staphylococcal protein A
#245IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
#246Compositions and methods for the treatment of immunodeficiency
#247Compositions and methods for the treatment of immunodeficiency
#248Antibodies or fragments thereof directed against a epitope of IsaA or IsaB
#249GENERATION OF HIGHLY POTENT ANTIBODIES NEUTRALIZING THE LUKGH (LUKAB) TOXIN OF STAPHYLOCOCCUS AUREUS
#250ADJUVANT THERAPY FOR STAPHYLOCOCCAL INFECTION WITH ENTEROTOXIN SPECIFIC MABS
#251Anti-wall teichoic antibodies and conjugates
#252POLYPEPTIDES AND IMMUNIZING COMPOSITIONS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE
#253Immunoglobulins and variants directed against pathogenic microbes
#254Anti-infective binding proteins that bind AIP2
#255Method for isolation of soluble polypeptides
#256Methods and Compositions Related to Immunizing Against Staphylococcal Lung Diseases and Conditions
#257HUMANIZED ANTIBODIES SPECIFIC FOR STAPHYLOCOCCAL ENTEROTOXIN B
#258IMMUNOGENIC COMPOSITION COMPRISING ALPHA-HEMOLYSIN OLIGOPEPTIDES
#259Treatment of staphylococcal disorders
#260COMPOSITIONS AND METHODS OF TREATING FUNGAL AND BACTERIAL PATHOGENS
#261Anti-antibody, method for manufacturing same, and usage of same
#262Purification platform for bispecific antibodies
#263Gram-positive bacteria specific binding compounds
#264Anti-staphylococcal antibodies
#265Compositions and methods related to antibodies that neutralize coagulase activity during disease
#266Anti-wall teichoic antibodies and conjugates
#267Compositions and methods for treating and preventing infections
#268Inert format
#269Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
#270IMMUNOGENIC COMPOSITION FOR USE IN VACCINATION AGAINST STAPHYLOCOCCEI
#271Proteins and nucleic acids useful in vaccines targeting
#272Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
#273BINDING MOIETIES FOR BIOFILM REMEDIATION
#274Antibodies to surface determinants
#275ANTIMICROBIAL COMPOSITIONS
#276Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
#277Methods of treating and preventing infections and associated conditions
#278Staphylococcal coagulase antigens and methods of their use
#279IMMUNOGENIC COMPOSITION COMPRISING AN INACTIVATED RECOMBINANT NON-PATHOGENIC BACTERIUM
#280Chromatography matrices including novel protein A based ligands
#281Protein A crystals and cross-linked crystals and methods of use thereof
#282Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
#283Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
#284Compositions and methods for phagocyte delivery of anti-staphylococcal agents
#285ANTI-POLY-N-ACETYL GLUCOSAMINE (PNAG) MONOCLONAL ANTIBODY AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF PNAG EXPRESSING BACTERIAL INFECTION
#286Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
#287Single-domain antibodies with improved thermal stability under cytoplasmic expression
#288BINDING MOIETIES FOR BIOFILM REMEDIATION
#289Dimeric protein with triple mutations
#290BINDING MOLECULES TARGETING PATHOGENS
#291Compositions and Methods for the Removal of Biofilms
#292Immunoglobulins and variants directed against pathogenic microbes
#293USE OF ALPHA-TOXIN FOR TREATING AND PREVENTING STAPHYLOCOCCUS INFECTIONS
#294Protective vaccine based on SA2493 protein
#295CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A IN COMPLEX WITH FIBRINOGEN DERIVED PEPTIDE AND USES THEREOF
#296Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
#297VACCINE COMPOSITION FOR PREVENTING STAPHYLLOCOCCUS AUREUS INFECTION
#298Identification of polynucleotides associated with a sample
#299Immunogenic compositions of antigens
#300ANTIBODY PRODUCTION METHODS